OliPass
Manufacturing · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
16-4 16 Beon-Gil Dongbaek Jungang-ro Fl ...Phone Number
+82 264882352Website
www.olipass.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About OliPass
OliPass Corporation is a public biotech company listed in KOSDAQ in South Korea (ticker: KQ244460). The company is developing RNA therapeutics based on its proprietary oligonucleotide platform called OPNA (Olipass Peptide Nucleic Acid). OPNA was derived from PNA by rational chemical modifications in order to improve the cell permeability and RNA affinity. For therapeutic intervention, OPNA potently binds to target pre-mRNA, induces exon skipping, and yields mRNA splice variant. Unlike other types of RNA therapeutics, OPNA does not require formulational aid for in vivo therapeutic activity.Explore more
OliPass Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OliPass your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on OliPass recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
OliPass, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once OliPass has new funding data
Check if OliPass has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at OliPass
Website visits: Recent activity has been detected on your website
Check out if OliPass is spiking on competitors!
Click to see if OliPass had a recent Job posting/layoffs
Product Launch: Get notified when OliPass launches new products
Recommended Actions
Reach out to Masked Content who joined OliPass as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
OliPass is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OliPass is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OliPass.
OliPass Tech Stack
A closer look at the technologies used by OliPass
OliPass News & Media
Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients
SEOUL, South Korea, March 16, 2023 /PRNewswire/ -- OliPass Corporation, an RNA therapeutics platform company, disclosed that OLP-1002, a selective inhibitor of Nav1.7 sodium ion channel, showed strong analgesic efficacy and long therapeutic duration according to interim findings from a placebo-controlled double blind multicenter Phase 2a study in chronic osteoarthritis patients with moderate to severe pain in Australia. In the Phase 2a study designed to evaluate 90 osteoarthritis (OA) patients iVanda Pharmaceuticals and OliPass Announce Strategic Partnership
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and OliPass Corporation (OliPass) (KOSDAQ: 24460) today announced that they have entered into a... Read More The post Vanda Pharmaceuticals and OliPass Announce Strategic Partnership appeared first on citybiz.OliPass Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002
SEOUL, South Korea, Feb. 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that the dosing of pain killer OLP-1002 commenced for a Phase 2a trial in osteoarthritis patients with pain. The Phase 2a study...SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 in Australia. In the Phase 2a trial of a two stage...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding OliPass
Sign Up For FreeTo access detailed company insights
OliPass Corporation is a public biotech company listed in KOSDAQ in South Korea (ticker: KQ244460). The company is developing RNA therapeutics based on its proprietary oligonucleotide platform called OPNA (Olipass Peptide Nucleic Acid). OPNA was derived from PNA by rational chemical modifications in order to improve the cell permeability and RNA af... Read More
